Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer. CDX-1307, the first candidate from the Company’s Precision Targeted Immunotherapy Platform, utilizes monoclonal antibodies to deliver vaccine directly to the patient’s immune system and focuses the immune system against hCG beta (hCG-β), a cancer-associated target believed to play a role in more aggressive forms of the disease. The data, presented at the 24th Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc) in Washington, D.C., demonstrated enhanced immunological and biological responses and support the planned initiation of Phase 2 clinical trials in hCG-β expressing cancers.